This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
CAMBRIDGE, Mass., Feb. 8, 2011 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that on February 8, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,884,187, entitled "Analysis of Amino Acid Copolymer Compositions." The patent includes claims to methods of preparing glatiramer acetate drug product. Glatiramer acetate is marketed as Copaxone®. Momenta is developing a generic version with Sandoz, who has filed an Abbreviated New Drug Application with the U.S. Food & Drug Administration for the product.
"This patent is an important addition to the Momenta intellectual property portfolio as it is the first U.S. patent to issue from our expanding portfolio of pending patent applications related to glatiramer acetate, also known as Copaxone®," stated Craig Wheeler, President and CEO of Momenta. "Protecting Momenta's innovative technology as it relates to this complex pharmaceutical product is an important strategic priority in the development of a generic version of Copaxone®."
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs.
To receive additional information about Momenta, please visit the website at
www.momentapharma.com , which does not form a part of this press release.
Forward Looking Statements
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to intellectual property, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "hope," "target," "project," "goals," "potential," "predict," "might," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Momenta from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Momenta is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.